Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
497259-23-1
3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1
4 nM and 15 nM for VEGFR2
Adenosine receptors: development of selective agonists and antagonists
Solubility: DMSO : ≥ 250 mg/mL (1435
Ripretinib rmectin B1a 497259-23-1Ripretinib (DCC 2618) is an orally bioavailable, selective KIT and PDGFRA switch control inhibitor. Ripretinib (DCC 2618) targets and binds to both wild type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild type and mutant forms. Ripretinib (DCC 2618) also inhibits multiple other kinase targets, such as
US$ 55.16
US$ 89.98
US$ 45.99
US$ 10.32
US$ 11.90
US$ 598.38
US$ 15.84